News from CROI 2011

aidsmap news from CROI 2011

More than twice the risk of failure for patients starting on abacavir with low CD4s or high viral loads, compared with tenofovir

A study published at the Conference on Retroviruses and Opportunistic Infections (CROI 2011) in February has found that patients starting therapy who either have viral loads over

Published
07 April 2011
By
Gus Cairns
‘Near perfect’ adherence in early stages of Partners PrEP study

Very high levels of adherence have been achieved in one of the ongoing randomised controlled trials of oral pre-exposure prophylaxis (PrEP), according to a poster presentation at

Published
29 March 2011
By
Gus Cairns
Gay men reduce their risk behaviour after HIV diagnosis, studies find, but disagree on how much by

Two studies presented at last month’s 18th Conference on Retroviruses and Opportunistic Infections (CROI 2011) both found that gay men diagnosed with HIV considerably reduce the amount

Published
25 March 2011
By
Gus Cairns
High rate of HCV reinfection after treatment of acute infection in Amsterdam gay men

Just over one-quarter of gay men with HIV successfully treated for acute hepatitis C infection became reinfected with hepatitis C within two years, almost all with a

Published
10 March 2011
By
Keith Alcorn
Is treatment really reducing infections?

This time last year, at the 17th Conference on Retroviruses and Opportunistic Infections (CROI), Dr Moupali Das of the San Francisco Department of Public Health presented evidence to

Published
09 March 2011
By
Gus Cairns
At least one in six patients maintains a viral load over one hundred thousand

A study of patients in southern Africa diagnosed during primary HIV infection has found that one in five maintained viral loads over 100,000 copies/ml for at least 400

Published
09 March 2011
By
Gus Cairns
Long-term HIV infection and poor inflammation control, not treatment, predicts risk of atherosclerosis

Long-term HIV infection is the only significant factor associated with thickening of the carotid intima media, a marker for atherosclerosis, a French case-control study has reported. A strong anti-inflammatory response

Published
07 March 2011
By
Keith Alcorn
Optimising infant HIV treatment in resource-limited settings: when can nevirapine be used?

Use of a lopinavir/ritonavir (LPV/r) based regimen compared to a nevirapine-based regimen in infants not exposed to single-dose nevirapine (sdNVP) was superior and the differences for viral failure, drug

Published
07 March 2011
By
Carole Leach-Lemens
Six months of nevirapine prophylaxis for breastfeeding infants reduces transmission by 76% if mother not on ART

Extending the use of daily infant nevirapine to six months reduced the risk of breastfeeding mother-to-child transmission by a significant 76% in HIV-positive mothers with CD4 cell

Published
07 March 2011
By
Carole Leach-Lemens
Partners study expands our knowledge of HIV transmission risk

A prevention study in which the intervention being tested failed is turning out to be a fertile source of information about HIV transmission risk in heterosexuals. Three

Published
03 March 2011
By
Gus Cairns
← First123Next →

The search for a cure

Zinc finger gene therapy produces HIV-resistant CD4 T-cells.

Read this news story >

Subscribe now

Email bulletins from NAM

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.